An in vitro method for predicting the likelihood that a patient suffering from KRAS wild type EGFR expressing colorectal cancer, metastatic colorectal cancer (mCRC), who is a candidate for treatment with an EGFR antibody, will respond to the treatment with said anti-EGFR antibody, comprising determining the expression level of prognostic genes or gene expression products thereof in a tissue sample, obtained from said patient by subjecting a nucleic acid sample from the tumor sample from the patient to PCR or an RNA or DNA array or a comparable diagnostic tool or apparatus, wherein (i) high expression compared to a reference value of the gene or gene product selected from the group of genes consisting of: ADAMDEC1, BSDC1, C1orf144, CAPZB, CDC42, DHCR7, DNAJC8, ECSIT, EXOSC10, FADS1, GBA, GLT25D1, GOSR2, IMPDH1, KLHL21, KPNA6, KPNB1, LSM12, MAN1B1, MIDN, PPAN, SH3BP2, SQLE, SSH3, TNFRSF1B, URM1, ZFYVE26, RGMB, SPIRE2, ABCC5, ACSL5, AOAH, AXIN2, CD24, CEACAM5, CEACAM6, ETS2, FMNL2, GPSM2, HDAC2, JUN, ME3, MED17, MYB, MYC, NEBL, NOSIP, PITX2, POF1B, PPARG, PPP1R14C, PRR15, PSMG1, RAB15, RAB40B, RNF43, RPS23, SLC44A3, SOX4, THEM2,VAV3, ZNF337, EPDR1, KCNK5, KHDRBS3, PGM2L1, STK38, and SHROOM2 indicates that the patient is likely to respond to said treatment, and (ii) high expression compared to a reference value of the gene or the gene product selected from the group of genes consisting of: C7orf46, CAST, DCP2, DIP2B, ERAP1, INSIG2, KIF21A, KLK6, NGRN, NRIP1, PHGDH, PPP1R9A, QPCT, RABEP1, RPA1,RPL22L1, SKP1, SLC25A27, SLC25A46, SOCS6, TPD52, ZDHHC2, ZNF654, ASB6, ATM, BMI1, CDC42EP2, EDEM3, PLLP, RALBP1, SLC4A11, TNFSF15, TPK1, C11orf9, C1QC, CABLES1, CDK6, EHBP1, EXOC6, EXT1, FLRT3, GCNT2, MTHFS, PIK3AP1, ST3GAL1, TK2, ZDHHC14, ARFGAP3, AXUD1, CAPZB, CHSY1, DNAJB9, GOLT1B, HSPA5, LEPROTL1, LIMS1, MAPK6, MYO6, PROSC, RAB8B, RAP2B, RWDD2B, SERTAD2, SOCS5, TERF2IP, TIAL1, TIPARP, TRIM8, TSC22D2, TGFA, VAPA, and UBE2K, indicates that the patient is likely not to respond to said treatment, wherein the reference value is defined by one or more of a specific functional or clinical property, and / or a specific expression profile and is obtained from a reference patient or patient group that does not express or express little of said gene or gene product, wherein said prognostic genes or gene expression products thereof include at least VAV3 and TGFa. (i) high expression compared to a reference value of the gene or gene product selected from the group of genes consisting of: ADAMDEC1, BSDC1, C1orf144, CAPZB, CDC42, DHCR7, DNAJC8, ECSIT, EXOSC10, FADS1, GBA, GLT25D1, GOSR2, IMPDH1, KLHL21, KPNA6, KPNB1, LSM12, MAN1B1, MIDN, PPAN, SH3BP2, SQLE, SSH3, TNFRSF1B, URM1, ZFYVE26, RGMB, SPIRE2, ABCC5, ACSL5, AOAH, AXIN2, CD24, CEACAM5, CEACAM6, ETS2, FMNL2, GPSM2, HDAC2, JUN, ME3, MED17, MYB, MYC, NEBL, NOSIP, PITX2, POF1B, PPARG, PPP1R14C, PRR15, PSMG1, RAB15, RAB40B, RNF43, RPS23, SLC44A3, SOX4, THEM2,VAV3, ZNF337, EPDR1, KCNK5, KHDRBS3, PGM2L1, STK38, and SHROOM2 indicates that the patient is likely to respond to said treatment, and (ii) high expression compared to a reference value of the gene or the gene product selected from the group of genes consisting of: C7orf46, CAST, DCP2, DIP2B, ERAP1, INSIG2, KIF21A, KLK6, NGRN, NRIP1, PHGDH, PPP1R9A, QPCT, RABEP1, RPA1,RPL22L1, SKP1, SLC25A27, SLC25A46, SOCS6, TPD52, ZDHHC2, ZNF654, ASB6, ATM, BMI1, CDC42EP2, EDEM3, PLLP, RALBP1, SLC4A11, TNFSF15, TPK1, C11orf9, C1QC, CABLES1, CDK6, EHBP1, EXOC6, EXT1, FLRT3, GCNT2, MTHFS, PIK3AP1, ST3GAL1, TK2, ZDHHC14, ARFGAP3, AXUD1, CAPZB, CHSY1, DNAJB9, GOLT1B, HSPA5, LEPROTL1, LIMS1, MAPK6, MYO6, PROSC, RAB8B, RAP2B, RWDD2B, SERTAD2, SOCS5, TERF2IP, TIAL1, TIPARP, TRIM8, TSC22D2, TGFA, VAPA, and UBE2K, indicates that the patient is likely not to respond to said treatment, wherein the reference value is defined by one or more of a specific functional or clinical property, and / or a specific expression profile and is obtained from a reference patient or patient group that does not express or express little of said gene or gene product, wherein said prognostic genes or gene expression products thereof include at least VAV3 and TGFa.